tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
InflaRx price target raised to $24 from $3 at Lucid Capital
PremiumThe FlyInflaRx price target raised to $24 from $3 at Lucid Capital
20d ago
Buy Rating for InflaRx: Promising Phase 2a Results of INF904 Drive Optimism
Premium
Ratings
Buy Rating for InflaRx: Promising Phase 2a Results of INF904 Drive Optimism
20d ago
InflaRx price target raised to $22 from $10 at Guggenheim
Premium
The Fly
InflaRx price target raised to $22 from $10 at Guggenheim
20d ago
Edesa Biotech and InflaRx: Advancing ARDS Treatment with Bevacizumab
PremiumCompany AnnouncementsEdesa Biotech and InflaRx: Advancing ARDS Treatment with Bevacizumab
1M ago
Edesa Biotech and InflaRx: Advancing ARDS Treatment with Vilobelimab
Premium
Company Announcements
Edesa Biotech and InflaRx: Advancing ARDS Treatment with Vilobelimab
1M ago
JUST BREATHE: A New Hope for ARDS Treatment and Market Impact
Premium
Company Announcements
JUST BREATHE: A New Hope for ARDS Treatment and Market Impact
1M ago
InflaRx: Buy Rating Based on Promising C5a/C5aR Strategy and Strong Financial Position
PremiumRatingsInflaRx: Buy Rating Based on Promising C5a/C5aR Strategy and Strong Financial Position
3M ago
InflaRx assumed with a Buy at H.C. Wainwright
Premium
The Fly
InflaRx assumed with a Buy at H.C. Wainwright
3M ago
InflaRx’s Hold Rating Amid Trial Delays and Uncertain Clinical Data
Premium
Ratings
InflaRx’s Hold Rating Amid Trial Delays and Uncertain Clinical Data
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100